Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 17, Number 10—October 2011

CME ACTIVITY - Research

Clinical Implications of Azole Resistance in Aspergillus fumigatus, the Netherlands, 2007–2009

Jan W.M. van der LindenComments to Author , Eveline Snelders, Greetje A. Kampinga, Bart J.A. Rijnders, Eva Mattsson, Yvette J. Debets-Ossenkopp, Ed J. Kuijper, Frank H. Van Tiel, Willem J.G. Melchers, Paul E. Verweij, and Kuijper

Author affiliations: Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands (J.W.M. van der Linden, E. Snelders, W.J.G. Melchers, P.E. Verweij); Groningen University Medical Centre, Groningen, the Netherlands (G.A. Kampinga); Erasmus Medical Centre, Rotterdam, the Netherlands (B.J.A. Rijnders); Utrecht University Medical Centre, Utrecht, the Netherlands (E. Mattsson); Vrije University Medical Centre, Amsterdam, the Netherlands (Y.J. Debets-Ossenkopp); Leiden University Medical Centre, Leiden, the Netherlands (E.J. Kuijper); Maastricht University Medical Centre, Maastricht, the Netherlands (F.H. van Tiel)

Main Article

Table 3

Underlying diseases of patients from whom azole-susceptible and -resistant Aspergillus fumigatus isolates were recovered, the Netherlands, 2007–2009

Underlying condition No. (%) patients with susceptible isolates, n = 1,129 No. (%) patients with resistant isolates, n = 63 p value*
Cystic fibrosis 365 (32.3) 17 (27.0) 0.38
Pulmonary disease, excluding cystic fibrosis 251 (22.2) 14 (22.2) 1.00
Hematologic/oncologic disease 125 (11.1) 13 (20.6) 0.02
Otorhinolaryngologic disease 63 (5.6) 3 (4.8) 0.78
Internal disease 85 (7.5) 8 (12.7) 0.14
Solid organ transplantation 26 (2.3) 2 (3.2) 0.66
Intensive care unit patient 31 (2.7) 2 (3.2) 0.84
Cardiac disease 9 (0.8) 1 (1.6) 0.50
Chronic granulomatous disease 5 (0.4) 0 0.60
Postoperative condition 23 (2.0) 1 (1.6) 0.81
Neurologic disease 2 (0.2) 0 0.74
Disease in children, not specified 4 (0.4) 0 0.64
Dermatologic disease 6 (0.5) 1 (1.6) 0.29
Other 91 (8.1) 1 (1.6)
Unknown 43 (3.8) 0

2 test.

2 test.

2 test.

Main Article

TOP